Perioperative Analgesia in Major Oncology operations for the prolepsis of persistence of Chronic Neuropathic Pain

IF 1 4区 医学 Q3 EMERGENCY MEDICINE
Signa Vitae Pub Date : 2021-09-15 DOI:10.22514/sv.2021.176
Dionysia Boura, Eirini Anastassopoulou, Paraskevi Koufopoulou, Koutouzis Stavros, Katsipoulakis Antonios, Papadopoulos George, V. Anastasia, Tsolou Archontia
{"title":"Perioperative Analgesia in Major Oncology operations for the prolepsis of persistence of Chronic Neuropathic Pain","authors":"Dionysia Boura, Eirini Anastassopoulou, Paraskevi Koufopoulou, Koutouzis Stavros, Katsipoulakis Antonios, Papadopoulos George, V. Anastasia, Tsolou Archontia","doi":"10.22514/sv.2021.176","DOIUrl":null,"url":null,"abstract":"Abstract: Perioperative Analgesia in Major Oncology operations for the prolepsis of persistence of Chronic Neuropathic Pain might include intravenous infusion of analgesics, concomitant drugs as well as invasive techniques in all surgical stages. Achieving highly effective analgesia presupposes the interdisciplinary collaboration of the surgeon and the anesthesiologist with the patient. Purpose: To give prominence to the benefits of analgetics for the oncology patient undergoing surgery after having received appropriate perioperative treatment and starts analgesic protection from the time preceding surgical incision to the patient’s complete recovery, as far as prevention of chronic neuropathic pain is concerned. Materials & methods: Thorough review of scientific literature in scientific databases (PubMed, Scopus, hesmo.org, uicc.org, Signa Vitae) which are consistent with the way our department functions and in compliance with the protocols concerning the prolepsis of persistence of Chronic Neuropathic Pain in major oncology operation patients. Results: Major analgesic outcomes and avoidance of persistence of chronic neuropathic pain, by taking into consideration the fact that postoperative oncology patients suffer from respiratory depression after invasive analgesia techniques. Also, we are prepared to reduce the use of opioids and their adverse effects, following the procedure below: (1) Choose, when allowed, a combination of general and epidural anesthesia to achieve maximum intraoperative and postoperative analgesia. (2) Intravenous administration of non-steroidal anti-inflammatories, paracetamol, dexamethasone 8mg, NMDA receptor antagonist (Ketamine 30 mg) before incision as well as local infusion of Ropivacaine 2% solution. (3) Intravenous infusion of lidocaine, fentanyl, remifentanil, morphine, tramadol, Mg, ketamine, during surgery by adjusting doses per patient and operative time. (4) Particular caution is suggested in the immediate postoperative period so as to avoid transition from acute postoperative pain to chronic neuropathic pain. Continue drop by drop administration of ropivacaine 2% from epidural catheter. Our armamentarium includes paracetamol, tramadol, dexketoprofen, oxycodone per os, PCA morphine, pain busters (paired drainage catheters with elastomeric pumps) of ropivacaine 2%, patch lidocaine and block nerve conduction. A medical record of the postoperative analgesic course of our patients is kept and completed by our medical and nursing staff.Conclusions: Perioperative analgesia is our key concern in all oncology patients undergoing major surgeries, so as to prevent persistence of chronic neuropathic pain, taking into consideration the impaired health status of patients with acute pain conditions.","PeriodicalId":49522,"journal":{"name":"Signa Vitae","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signa Vitae","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22514/sv.2021.176","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Perioperative Analgesia in Major Oncology operations for the prolepsis of persistence of Chronic Neuropathic Pain might include intravenous infusion of analgesics, concomitant drugs as well as invasive techniques in all surgical stages. Achieving highly effective analgesia presupposes the interdisciplinary collaboration of the surgeon and the anesthesiologist with the patient. Purpose: To give prominence to the benefits of analgetics for the oncology patient undergoing surgery after having received appropriate perioperative treatment and starts analgesic protection from the time preceding surgical incision to the patient’s complete recovery, as far as prevention of chronic neuropathic pain is concerned. Materials & methods: Thorough review of scientific literature in scientific databases (PubMed, Scopus, hesmo.org, uicc.org, Signa Vitae) which are consistent with the way our department functions and in compliance with the protocols concerning the prolepsis of persistence of Chronic Neuropathic Pain in major oncology operation patients. Results: Major analgesic outcomes and avoidance of persistence of chronic neuropathic pain, by taking into consideration the fact that postoperative oncology patients suffer from respiratory depression after invasive analgesia techniques. Also, we are prepared to reduce the use of opioids and their adverse effects, following the procedure below: (1) Choose, when allowed, a combination of general and epidural anesthesia to achieve maximum intraoperative and postoperative analgesia. (2) Intravenous administration of non-steroidal anti-inflammatories, paracetamol, dexamethasone 8mg, NMDA receptor antagonist (Ketamine 30 mg) before incision as well as local infusion of Ropivacaine 2% solution. (3) Intravenous infusion of lidocaine, fentanyl, remifentanil, morphine, tramadol, Mg, ketamine, during surgery by adjusting doses per patient and operative time. (4) Particular caution is suggested in the immediate postoperative period so as to avoid transition from acute postoperative pain to chronic neuropathic pain. Continue drop by drop administration of ropivacaine 2% from epidural catheter. Our armamentarium includes paracetamol, tramadol, dexketoprofen, oxycodone per os, PCA morphine, pain busters (paired drainage catheters with elastomeric pumps) of ropivacaine 2%, patch lidocaine and block nerve conduction. A medical record of the postoperative analgesic course of our patients is kept and completed by our medical and nursing staff.Conclusions: Perioperative analgesia is our key concern in all oncology patients undergoing major surgeries, so as to prevent persistence of chronic neuropathic pain, taking into consideration the impaired health status of patients with acute pain conditions.
肿瘤大手术围手术期镇痛治疗慢性神经源性疼痛的持续性
摘要:在主要肿瘤手术中,为缓解慢性神经性疼痛的持续性,围手术期镇痛可能包括在所有手术阶段静脉输注止痛药、伴随药物以及侵入性技术。实现高效镇痛需要外科医生和麻醉师与患者进行跨学科合作。目的:就慢性神经性疼痛的预防而言,突出镇痛药对接受手术的肿瘤患者在接受适当围手术期治疗后的益处,并从手术切口前到患者完全康复开始镇痛保护。材料和方法:对科学数据库(PubMed、Scopus、hesmo.org、uicc.org、Signa Vitae)中的科学文献进行全面审查,这些文献与我们部门的运作方式一致,并符合关于主要肿瘤手术患者慢性神经性疼痛持续性的预防方案。结果:主要的镇痛效果和避免慢性神经性疼痛的持续性,考虑到肿瘤术后患者在使用侵入性镇痛技术后会出现呼吸抑制。此外,我们准备减少阿片类药物的使用及其不良反应,遵循以下程序:(1)在允许的情况下,选择全身麻醉和硬膜外麻醉的组合,以实现最大限度的术中和术后镇痛。(2) 切口前静脉注射非甾体抗炎药、扑热息痛、地塞米松8mg、NMDA受体拮抗剂(氯胺酮30mg)以及局部输注2%罗哌卡因溶液。(3) 通过调整每位患者的剂量和手术时间,在手术期间静脉输注利多卡因、芬太尼、瑞芬太尼、吗啡、曲马多、镁、氯胺酮。(4) 建议在术后立即特别小心,以避免从急性术后疼痛转变为慢性神经性疼痛。继续从硬膜外导管逐滴给药2%罗哌卡因。我们的药物包括扑热息痛、曲马多、右酮洛芬、口服羟考酮、PCA吗啡、2%罗哌卡因止痛片(带弹性泵的配对引流导管)、利多卡因贴片和阻断神经传导。我们的医护人员保存并完成患者术后镇痛过程的医疗记录。结论:考虑到急性疼痛患者的健康状况受损,在所有接受大手术的肿瘤患者中,围手术期镇痛是我们关注的重点,以防止慢性神经性疼痛的持续存在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Signa Vitae
Signa Vitae 医学-急救医学
CiteScore
1.30
自引率
9.10%
发文量
0
审稿时长
3 months
期刊介绍: Signa Vitae is a completely open-access,peer-reviewed journal dedicate to deliver the leading edge research in anaesthesia, intensive care and emergency medicine to publics. The journal’s intention is to be practice-oriented, so we focus on the clinical practice and fundamental understanding of adult, pediatric and neonatal intensive care, as well as anesthesia and emergency medicine. Although Signa Vitae is primarily a clinical journal, we welcome submissions of basic science papers if the authors can demonstrate their clinical relevance. The Signa Vitae journal encourages scientists and academicians all around the world to share their original writings in the form of original research, review, mini-review, systematic review, short communication, case report, letter to the editor, commentary, rapid report, news and views, as well as meeting report. Full texts of all published articles, can be downloaded for free from our web site.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信